BeiGene reported a significant turnaround in its financial performance, achieving its first full-year profitability in 2025 with a net income attributable to shareholders of 1.461 billion CNY, following years of losses. In Q1 2026, the company posted a net profit of 1.608 billion CNY, reversing a net loss of 94.503 million CNY from the same period the previous year. The company's revenue for 2025 reached 38.225 billion CNY, reflecting a year-on-year increase of approximately 30%, driven largely by strong global sales of its BTK inhibitor Brukinsa, which generated 28.067 billion CNY in 2025, growing nearly 50% year over year. Additionally, BeiGene's Q1 2026 revenue was reported at 10.544 billion CNY, up 31% year-on-year, supported by higher product sales and improved cost management. The company also issued guidance for 2026, expecting revenue between $6.3 billion and $6.5 billion, indicating anticipated growth compared to prior periods.